There’s more to IgE – Let’s Talk Severe Asthma - European Medical Journal

This site is intended for healthcare professionals

There’s more to IgE – Let’s Talk Severe Asthma

Respiratory
Download PDF
Chairperson:
Roland Buhl 1
Speakers:
Gary Anderson , 2 William Busse , 3 Jan Lötvall , 4 David Price 5
Acknowledgements:

Writing assistance was provided by Dr Nicola Ray apothecom scopemedical.

Citation:
EMJ Respir. ;2:28-32. DOI/10.33590/emjrespir/10312527. https://doi.org/10.33590/emjrespir/10312527.
Support:

Medical writing assistance was funded by Novartis. The views and opinions expressed are those of the authors as expressed during the symposium and not necessarily of Novartis.

Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.

Meeting Summary

The meeting discussed the current understanding of the role of immunoglobulin E (IgE) in asthma, and anti-IgE strategies in the treatment of severe asthma. Prof Gary Anderson provided an overview of the integral role of IgE in the inflammatory pathways involved in the pathogenesis of severe asthma and the development of omalizumab (Xolair®), an anti-IgE therapy. Prof William Busse presented some of the clinical findings on the use of omalizumab for virus-provoked asthma. Prof Jan Lötvall discussed how phenotyping could improve the development of patient-targeted treatment strategies in asthma. Finally, Prof David Price discussed how changes to the clinical management of patients with severe asthma could improve patient outcomes.

Please view the full content in the pdf above.

Rate this content's potential impact on patient outcomes

Average rating / 5. Vote count:

No votes so far! Be the first to rate this content.